AVITA Medical (RCEL) said Monday that the US Food and Drug Administration has approved its premarket approval supplement for Recell Go Mini.
The Recell Go Mini disposable cartridge, which is a line extension of the Recell Go system, was designed specifically to treat smaller wounds of up to 480 square centimeters, the company said.
AVITA said the rollout will start with trauma and burn centers that treat smaller wounds during Q1 2025.
The shares of AVITA Medical rose 4.3% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。